Beam Therapeutics

BEAM · NASDAQ

$24.93+$0.74 (+3.06%)TodayMarket closed · Oct 20, 7:58 PM ET

Prev close $24.19

About BEAM

Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. The company is headquartered in Cambridge, Massachusetts and currently employs 511 full-time employees. The company went IPO on 2020-02-06. The firm's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

Employees: 511
Headquarters: Cambridge, Massachusetts
Listed: Feb 6, 2020
Sector: Health Care
Industry: Biotechnology
Website: beamtx.com

Leadership

Beam Therapeutics executives
Name	Title	Since	Age
Giuseppe Ciaramella	—	—	56
John Evans	—	2017	47
Sravan Emany	—	—	47
Amy Simon	—	—	61
Christine Bellon	—	—	60
Mark Fishman	—	—	74
Graham Cooper	—	—	55
Chirfi Guindo	—	—	59
Carole Ho	—	—	52
John Maraganore	—	—	62
Christi Shaw	—	—	58
Kathleen Walsh	—	—	69

Suppliers and customers

Price correlation is over one year: 1 means the stocks move together, -1 opposite

Beam Therapeutics suppliers and customers
Company	Relationship	Country	Correlation
Editas Medicine EDIT	Supplier and customer	US	0.90
Oxford BioMedica OXB.L	Supplier and customer	GB	0.85
Sana Biotechnology SANA	Supplier and customer	US	0.83
Magenta Therapeu MGTA	Supplier and customer	US	0.69
ChemoMetec CHEMM.CO	Supplier	DK	0.57
Apellis Pharmaceuticals APLS	Supplier and customer	US	0.25
Pfizer PFE	Supplier and customer	US	-0.51
Verve Therapeutics VERV	Supplier and customer	US	—
Broad Institute, Inc.	Supplier and customer	US	—
Harvard College	Supplier and customer	US	—

Similar companies

Companies in the same industry as Beam Therapeutics

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.